Lumacaftor
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Lumacaftor: From Cystic Fibrosis to Leprosy
One-Sentence Summary
Lumacaftor is a CFTR corrector originally developed to treat cystic fibrosis by correcting F508del-CFTR protein misfolding. The TxGNN model predicts it may be effective for Leprosy, but currently there are 0 clinical trials and 0 publications supporting this direction — the prediction rests on model inference alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cystic Fibrosis (F508del-CFTR) |
| Predicted New Indication | Leprosy |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L5 |
| Germany Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (Data Gap). Based on known information, Lumacaftor is a CFTR corrector whose established pharmacology focuses on correcting F508del-CFTR protein misfolding, and its efficacy in cystic fibrosis is well proven.
The relationship between cystic fibrosis and leprosy is not mechanistically established. Leprosy is caused by Mycobacterium leprae infection, with pathogenesis driven by immune evasion and peripheral nerve invasion — processes with no known direct link to CFTR correction. Some literature speculates that CFTR channel function may influence macrophage phagocytosis and innate immune responses, which could theoretically connect to mycobacterial clearance, but this remains a speculative association without experimental or clinical data specific to mycobacterial infection.
The absence of original MOA data further increases the uncertainty of this mechanistic assessment. Given the lack of any supporting clinical or literature evidence, this prediction should be treated as a hypothesis-generating signal only, not a basis for clinical action.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Germany Market Information
Lumacaftor currently has no market authorizations on record (total_licenses = 0); the drug is not marketed under the reviewed regulatory scope.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is supported only by TxGNN model inference (Evidence Level L5), with zero clinical trials and zero publications, and the proposed mechanistic link between CFTR correction and M. leprae pathogenesis is speculative and unvalidated. There is insufficient evidence to advance this candidate at this time.
To proceed, the following is needed:
- Complete original MOA data via DrugBank query (DG002)
- Obtain TFDA package insert warnings/contraindications for baseline safety screening (DG001, Blocking)
- Preclinical/in-vitro studies examining CFTR modulation and macrophage response to M. leprae or related mycobacteria
- Updated literature search specifically targeting "CFTR modulators" + "mycobacterial infection" or "leprosy"
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.